经与会董事审议表决，一致通过如下议案： 证券代码：603087 证券简称：甘李药业 公告编号：2025-058 甘李药业股份有限公司 第五届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 甘李药业股份有限公司（"公司"）第五届董事会第三次会议于 2025 年 7 月 26 日以电子邮件方式发出会议通知和会议材料，2025 年 8 月 6 日在公司五层会 议室以现场结合通讯方式召开。本次会议由董事长陈伟先生主持。应出席董事 9 名，实际出席董事 9 名，公司监事及高级管理人员列席本次会议。本次会议的召 开符合《公司法》和《公司章程》的有关规定，会议决议合法有效。 二、董事会会议审议情况 表决结果：9 票同意、0 票反对、0 票弃权。 公司审计委员会已对本议案进行事前审议，并发表了同意的意见。 （一）审议通过了《关于公司 2025 年半年度报告及摘要的议案》 同意《甘李药业股份有限公司 2025 年半年度报告》及其摘要。 具体内容详见公司于同日在上海证券交易所网站披露的《甘李药业股 ...

甘李药业股份有限公司 2025 年半年度报告 公司代码：603087 公司简称：甘李药业 甘李药业股份有限公司 2025 年半年度报告 1 / 158 甘李药业股份有限公司 2025 年半年度报告 董事长兼 CEO 致辞 ——研发为重，薪火相传 尊敬的各位投资者和朋友们： 站在 2025 年年中这一重要时间节点，心怀敬畏与感恩，我从公司创始人甘忠如博士手上接过 甘李药业董事长的接力棒。面对公司辉煌的历史积淀和各位的殷切期望，我深知这份使命的重量。 我唯有以最诚挚的心肩负起这份责任，以最坚定的行动去擘画未来蓝图，以最出色的成绩去回应 公司全体股东的信任。 荏苒廿七载，公司稳步向前 1998 年，甘忠如博士创办甘李药业。成立不到一年，甘博士带领团队便成功研发出了中国第 一支第三代胰岛素，成功打破国外垄断，使中国成为全世界第三个能够生产基因重组人胰岛素的 国家。时光飞逝，甘李药业已走过 27 个春秋。时光洗礼，岁月沉淀，给公司留下的是弥足珍贵的 研发经验，是敏锐清晰的市场洞察，是坚固深厚的销售渠道，是稳健扎实的发展步伐。我本人从 最初的研发岗位一路走来，深知技术创新的力量，纵使角色转变，但"研发为重"的初心，自己 ...

Core Viewpoint - Ganli Pharmaceutical (603087) reported significant growth in its financial performance for the first half of 2025, with notable increases in both revenue and net profit [1] Financial Performance - The company achieved a revenue of 2.067 billion yuan, representing a year-on-year growth of 57.18% [1] - The net profit attributable to shareholders reached 604 million yuan, marking a year-on-year increase of 101.96% [1] - Basic earnings per share were reported at 1.02 yuan [1] Product Performance - The sales volume and revenue of insulin preparations in the domestic market showed significant growth during the first half of 2025 [1]

甘李药业公告，2025年上半年营业收入20.67亿元，同比增长57.18%。净利润6.04亿元，同比增长 101.96%。 ...

Core Viewpoint - Gannee Pharmaceutical's stock price increased by 1.05% to 64.36 yuan as of August 6, 2025, with a notable intraday rebound and a peak of 65.90 yuan [1] Company Overview - Gannee Pharmaceutical specializes in the biopharmaceutical sector, focusing on the research, production, and sales of diabetes treatment drugs, including insulin analogs and human insulin [1] Market Performance - The trading volume on August 6 reached 1.322 billion yuan, with a turnover rate of 3.65% [1] - The net inflow of main funds on August 6 was 69.8268 million yuan, with a cumulative net inflow of 153 million yuan over the past five days [1] - The current total market capitalization of the company is 38.685 billion yuan, while the circulating market value stands at 36.132 billion yuan [1]

天眼查商业履历信息显示，甘李药业股份有限公司，成立于1998年，位于北京市，是一家以从事医药制 造业为主的企业。企业注册资本60106.529万人民币，实缴资本60106.529万人民币。公司法定代表人为 陈伟。 通过天眼查大数据分析，甘李药业股份有限公司共对外投资了6家企业，参与招投标项目2427次，知识 产权方面有商标信息190条，专利信息103条，此外企业还拥有行政许可449个。 来源：金融界 金融界消息 截至2025年8月6日收盘，甘李药业（603087）报收于64.36元，上涨1.05%，换手率3.65%， 成交量20.48万手，成交金额13.22亿元。 资金流向方面，今日主力资金净流入6982.68万元，占比成交额5.28%。其中，超大单净流入5078.40万 元、占成交额3.84%，大单净流入1904.28万元、占成交额1.44%，中单净流出流出5729.25万元、占成交 额4.33%，小单净流出1253.43万元、占成交额0.95%。 甘李药业最新一期业绩显示，截至2025一季报，公司营业总收入9.85亿元、同比增长75.76%，归属净利 润3.12亿元，同比增长224.90%，扣非净利润2. ...

金融界消息 截至2025年8月5日收盘，甘李药业（603087）报收于63.69元，上涨0.65%，换手率3.47%， 成交量19.48万手，成交金额12.43亿元。 资金流向方面，今日主力资金净流入4266.56万元，占比成交额3.43%。其中，超大单净流入3873.58万 元、占成交额3.12%，大单净流入392.98万元、占成交额0.32%，中单净流出流出1940.72万元、占成交 额1.56%，小单净流出2325.84万元、占成交额1.87%。 甘李药业最新一期业绩显示，截至2025一季报，公司营业总收入9.85亿元、同比增长75.76%，归属净利 润3.12亿元，同比增长224.90%，扣非净利润2.15亿元，同比增长1150.17%，流动比率4.917、速动比率 3.514、资产负债率7.91%。 天眼查商业履历信息显示，甘李药业股份有限公司，成立于1998年，位于北京市，是一家以从事医药制 造业为主的企业。企业注册资本60106.529万人民币，实缴资本60106.529万人民币。公司法定代表人为 陈伟。 通过天眼查大数据分析，甘李药业股份有限公司共对外投资了6家企业，参与招投标项目2427次， ...

Core Viewpoint - Gann Li Pharmaceutical Co., Ltd. has shown significant financial growth in the first quarter of 2025, with a notable increase in revenue and net profit, indicating strong operational performance and potential investment opportunities [1][2]. Financial Performance - As of the first quarter of 2025, Gann Li reported total revenue of 985 million yuan, representing a year-on-year growth of 75.76% [1]. - The company's net profit attributable to shareholders reached 312 million yuan, a year-on-year increase of 224.90% [1]. - The non-recurring net profit was 215 million yuan, showing a remarkable year-on-year growth of 1150.17% [1]. - The liquidity ratios are strong, with a current ratio of 4.917 and a quick ratio of 3.514, while the debt-to-asset ratio stands at 7.91% [1]. Market Activity - On August 4, 2025, Gann Li's stock closed at 63.26 yuan, up 3.72%, with a turnover rate of 4.55% and a trading volume of 255,400 hands, amounting to a transaction value of 1.579 billion yuan [1]. - The net inflow of main funds was 186 million yuan, accounting for 11.89% of the transaction value, with large orders contributing a net inflow of 112 million yuan [1]. Company Background - Gann Li Pharmaceutical Co., Ltd. was established in 1998 and is based in Beijing, primarily engaged in the pharmaceutical manufacturing industry [2]. - The company has a registered capital of 6.0106529 billion yuan and has made investments in six enterprises, participated in 2,427 bidding projects, and holds 190 trademark registrations and 103 patents [2].

Core Insights - The event held on August 2 in Beijing aimed to connect high-level talents with quality enterprises, significantly enhancing the recruitment efforts for the city's sub-center development [1][16] - Nearly 50 key enterprises participated, offering over 600 quality job positions, showcasing the sub-center's strong appeal to high-end talent [1][3] Talent Attraction - The recruitment event attracted over 1,400 candidates, with nearly 1,000 attending in person, resulting in 500 preliminary employment intentions [3] - The talent pool was diverse, including 251 overseas returnees and 310 individuals with master's degrees or higher, indicating a high level of educational attainment [5] Industry Alignment - Popular sectors among candidates included finance, internet, AI, advertising, media, culture, and sports, aligning well with the sub-center's key industries [7] - Participating companies included major players such as Industrial and Commercial Bank of China, Mengniu Dairy, and China Three Gorges Corporation, reflecting a rich variety of industry representation [8] Event Experience - The event featured a high level of engagement, with candidates actively interacting with HR representatives, leading to a positive experience for job seekers [12][14] - Specialized service areas, such as career planning and policy consultation, attracted significant attention, with over 500 and 1,500 visits respectively [14] Future Initiatives - The event organizer plans to follow up on the employment status of interested candidates and introduce more workplace experiences and internship opportunities [16] - The local talent bureau aims to optimize employment services and maintain a consistent recruitment effort to support the sub-center's high-quality development [20]

Group 1: Investor Meeting Announcement - The company will hold a half-year performance briefing on August 13, 2025, from 10:00 to 11:00 AM [2][8] - Investors can submit questions from August 6 to August 12, 2025, via the Shanghai Stock Exchange Roadshow Center or the company's email [2][9] - The meeting will be conducted in an interactive online format, allowing for real-time communication with investors [3] Group 2: Attendance and Participation - Key personnel attending the meeting include the Chairman, General Manager, Independent Director, and other senior management [4] - Investors can participate in the meeting by logging into the Shanghai Stock Exchange Roadshow Center [6][7] - The meeting will be accessible online, and investors can view the main content afterward [10] Group 3: Share Buyback Progress - The company approved a share buyback plan on September 5, 2024, with a maximum price of RMB 62.76 per share and a total buyback fund between RMB 150 million and RMB 300 million [12] - As of July 31, 2025, the company has repurchased 3.540021 million shares, accounting for 0.5890% of the total share capital, with a total expenditure of approximately RMB 150.07 million [15] - The purpose of the buyback has been adjusted from employee stock ownership plans to reducing the company's registered capital [13]